CDKN2A and head and neck squamous cell carcinoma: In line with these results the EXTREME trial showed that addition of cetuximab to the standard chemotherapy resulted in improved OS as well as PFS, both in p16INK4a/HPV+ and p16INK4a/HPV− HNSCC [45,48].